Sign In
Buy SHIEF
$0.0800
+0 (+0%)
At Close: Jun 02, 2026
Shield Therapeutics higher on Accrufer update
09:21am, Friday, 21'st May 2021
Shield Therapeutics PLC (LON:STX) rose 4% to 60.08p in the early afternoon after stating it remains on track to launch Accrufer, its iron deficiency treatment, in the US by the end of next month. The
Shield Therapeutics doing its homework ahead of launch next month of Accrufer in the US
04:21am, Friday, 21'st May 2021
Shield Therapeutics PLC (LON:STX) said it remains on track to launch Accrufer, its iron deficiency treatment, in the US by the end of next month. The commercial-stage pharmaceutical company said that
Shield Therapeutics doing its homework ahead of launch next month of Acrrufer in the US
03:27am, Friday, 21'st May 2021
Shield Therapeutics PLC (LON:STX) said it remains on track to launch Accrufer, its iron deficiency treatment, in the US by the end of next month. The commercial-stage pharmaceutical company said that
Shield Therapeutics prepares for American launch of Accrufer
03:24am, Friday, 21'st May 2021
Evidence from clinical studies shows it provides long-term treatment for maintaining the body's iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms.
Shield Therapeutics says study demonstrates long-term effectiveness of ferric maltol
03:05am, Tuesday, 18'th May 2021
Shield Therapeutics PLC (LON:STX, OTCQX:SHIEF), developer of a breakthrough new product for anaemia, noted a recent publication in the journal Inflammatory Bowel Diseases of the positive long-term ef
